Lund based Asgard Therapeutics aims to turn tumor cells into a type of dendritic cell inside the body so that the immune system can learn the tumor's signature and fight it systemically

Jun 9
1 min read

Co-Founder and CEO Cristiana Pires describes this unique approach, which is in late stage pre-IND work and recently was presented at AACR and ASGCT. The company already has an impressive roster of investors backing it.

https://vimeo.com/1199790242

Recent Posts

See All

Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads

Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month

San Diego based Replicate Bioscience believes that self-replicating RNA (srRNA) has key advantages over linear or circular RNA. Last year Novo signed on as a partner in obesity and diabetes

Lund based Asgard Therapeutics aims to turn tumor cells into a type of dendritic cell inside the body so that the immune system can learn the tumor's signature and fight it systemically

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight